Corcept Therapeutics (CORT) CDO logs plan-based purchase and 498-share grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Corcept Therapeutics Chief Development Officer William Guyer reported two stock acquisitions. On March 2, 2026, he acquired 498 shares of common stock at $35.97 per share under a purchase plan and received an additional 498 restricted shares at no cost. After these transactions, he directly owned 2,231 shares, including unvested restricted stock awards that vest after one year if specified service and ownership conditions are met.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Guyer William

Role Chief Development Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	498	$35.97	$18K
Grant/Award	Common Stock	498	$0.00	--

Holdings After Transaction: Common Stock — 1,733 shares (Direct)

Footnotes (1)

The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 2, 2026. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

Form 4 Insider Transactions: What Each Field Means →

03/04/2026 - 08:21 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guyer William

(Last)

(First)

(Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY

94065

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/02/2026		A		498⁽¹⁾	A	$35.97⁽²⁾	1,733⁽³⁾	D
Common Stock	03/02/2026		A		498⁽⁴⁾	A	$0	2,231⁽³⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on March 2, 2026.

2. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

3. Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

4. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer.	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did William Guyer report in his latest Form 4 for CORT?

William Guyer reported acquiring 498 common shares at $35.97 and receiving 498 restricted shares on March 2, 2026. These transactions were made under Corcept Therapeutics’ 2024 Incentive Award Plan and a related purchase plan, increasing his direct holdings to 2,231 shares.

How many Corcept Therapeutics shares does William Guyer own after this Form 4?

After the reported transactions, William Guyer directly owns 2,231 Corcept Therapeutics common shares. This total includes previously granted restricted stock awards and new restricted shares that will vest after one year if he meets specified service and purchase plan ownership conditions.

What price did William Guyer pay for CORT shares under the purchase plan?

Under the purchase plan, William Guyer purchased 498 CORT common shares at $35.97 per share on March 2, 2026. A footnote explains the price was set according to the closing market price on the purchase date, consistent with the company’s 2024 Incentive Award Plan.

What restricted stock awards did William Guyer receive in this Form 4?

William Guyer received 498 restricted common shares at a price of $0.00 per share on March 2, 2026. These shares were granted under a purchase plan and will fully vest one year after the grant date if he remains the beneficial owner of the related purchase plan shares.

When do William Guyer’s unvested Corcept restricted stock awards vest?

A prior 224-share restricted stock grant from December 1, 2025 vests 100% after one year if employment-related requirements are met. The 498 new restricted shares vest 100% one year after grant, provided he continues as beneficial owner of the purchase plan shares over that period.

Under which plan were William Guyer’s CORT transactions executed?

The purchases and restricted stock awards were executed under Corcept Therapeutics’ 2024 Incentive Award Plan and an associated purchase plan. The plan sets the purchase price using the closing market price and provides restricted stock awards that vest after one year if specified conditions are satisfied.